“confirmation hearings are set for well, they're not set, but they're expected when the summer recess for the US Senate is finished.”
→ Read the source episode
Senate confirmation hearings for Heidi Overton as FDA commissioner are scheduled and held.
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Greg Suvannovich predicts EyePoint's second phase three trial data will be available in October 2026.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.